Clinical Trial

Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The goal of this clinical research study is to learn if ONC-PluReceptor NK cell therapy (combined with the monoclonal antibody therapies epcoritamab and tafasitamab) can help to control relapsed or refractory B-cell Non-Hodgkin Lymphoma. The safety of this treatment will also be studied.
Protocol Amendment History 1 change
critical Recruitment opened 2026-05-02
Trial Details
NCT Number NCT07283679
Lead Sponsor M.D. Anderson Cancer Center
Conditions Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-cell Non-Hodgkin Lymphoma
Enrollment 30 participants
Start Date 2026-02-24
Primary Completion 2031-09-30 (estimated)
Study Completion 2033-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-01